Design Therapeutics (DSGN) Operating Leases (2021 - 2026)

Design Therapeutics' Operating Leases history runs 6 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• In Q1 2026, Operating Leases rose 66.52% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (up 66.52% YoY), while the FY2025 annual figure was $645000.0, down 57.95% from the prior year.
• Operating Leases came in at $2.2 million for Q1 2026 at Design Therapeutics, up from $645000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $3.4 million in Q2 2022 to a low of $645000.0 in Q4 2025.
• A 5-year average of $2.2 million and a median of $2.2 million in 2026 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases sank 57.95% in 2025 and soared 66.52% in 2026, its largest moves.
• Design Therapeutics' Operating Leases stood at $3.1 million in 2022, then retreated by 23.5% to $2.3 million in 2023, then sank by 34.28% to $1.5 million in 2024, then tumbled by 57.95% to $645000.0 in 2025, then jumped by 240.78% to $2.2 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $2.2 million, $645000.0, and $877000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison